Resverlogix's Lead Drug Featured in Key Scientific Publication

Calgary, Canada (ots/PRNewswire) -

- RVX-208 is the Only Apo-Al/HDL Drug to be Highlighted

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is
pleased to announce that Resverlogix's lead drug is featured
prominently in an article titled "Emerging Antidyslipidemic Drugs",
which appears in the current edition of Expert Opinion of Emerging
Drugs, a well respected scientific journal for the pharmaceutical
industry. The article written by Drs.' Pollex, Joy and Hegele
provides an overview of current and upcoming dyslipidemic drugs.

"To be the only ApoA-l/HDL drug highlighted in an esteemed
journal such as Expert Opinion of Emerging Drugs speaks volumes as to
the excitement felt in the scientific community for our lead drug
RVX-208," stated Donald McCaffrey, President and CEO of Resverlogix.
"The data provided to the authors was our preclinical data. The Phase
1a data which we recently announced illustrated very similar trending
as the African Green Monkey data of increased ApoA-I production and
HDL functionality, thus our enthusiasm continues to build as we head
into our Phase 1b/2a trial later this year."

RVX-208 is a first-in-class small molecule that facilitates
endogenous ApoA-I production. It is positioned as one of the most
promising emerging drugs in the treatment of atherosclerosis, the
largest medical market in the world with a critical unmet need. To
the Company's knowledge RVX-208 is the only novel small molecule that
is specifically designed to increase ApoA-I production. Consequently
this raises functional HDL levels which in turn enhance reverse
cholesterol transport, atherosclerosis regression and ultimately
reduction of major adverse cardiovascular events (MACE).

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's disease and other vascular
disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

For further information:
Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp.,
Phone: +1-604-538-7072,
Email: Theresa@resverlogix.com;
Ken Lebioda, SVP Business & Corporate Dev't, Resverlogix Corp.,
Phone: +1-403-254-9252,
Email: Ken@resverlogix.com;
Website: http://www.resverlogix.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email:
Theresa@resverlogix.com; Ken Lebioda, SVP Business & Corporate Dev't,
Resverlogix Corp., Phone: +1-403-254-9252, Email:
Ken@resverlogix.com; Website: http://www.resverlogix.com